Physician profile
Stanley Flemming
NPI 1790803443
$2,148.72
in general payments reported to CMS, 2019-2025
12 companies · $432 in 2025
The $432 reported for 2025 was more than what a typical Adolescent Medicine (Family Medicine) provider received nationally (typical 2025 total: $135).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $672 · 2020: $69.88 · 2021: $282 · 2022: $174 · 2023: $256 · 2024: $262 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $950.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $583.21 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $388.90 | 2021-2025 | Lokelma, Farxiga |
| Lilly USA, LLC | $363.93 | 2019-2023 | Trulicity, Humalog, Basaglar |
| Teva Pharmaceuticals USA, INC. | $210.52 | 2024-2025 | Austedo Xr, Austedo Xr |
| Insmed, INC. | $174.34 | 2025 | Brinsupri, Arikayce |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Kyowa Kirin, INC. | $124.99 | 2021 | |
| Novo Nordisk INC | $91.18 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Avanir Pharmaceuticals, INC. | $39.19 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.39 | 2024 | |
| Alnylam Pharmaceuticals INC. | $15.17 | 2025 | Amvuttra |
| Otsuka America Pharmaceutical, INC. | $13.90 | 2025 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Flemming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.